Sanofi MS Drug Receives EU Approval Recommendation
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sanofi's multiple sclerosis drug, previously rejected by the FDA, received a recommendation for approval from European regulators.
- Regeneron cut a pricing deal with the Trump administration, a move noted amid the administration’s legal battles.
- European regulators gave a positive review for the Sanofi drug, contrasting the FDA’s earlier denial.
- FDA is testing new coverage pathways for medical devices, reflecting a broader push for faster approvals.
- Medicare is exploring creative coverage models for medical devices, aligning with FDA initiatives.
Why it matters: Not enough in the article to say why this matters.
